Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
SPONSORED CONTENTA Modern Approach to Parasite PreventionWith evolving parasite threats, traditional preventatives may not be enough. Discover how innovation is changing the landscape of protection. + Learn More